小背光区设计对角膜折射疗法 (CRT) 近视控制的有效性:为期一年的前性队列研究
Xuewei Li1,2,3,4,5, Lili Zuo1,2,3,4,5, Heng Zhao1,2,3,4,5
1Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
Eye and vision (London, England)
|November 21, 2023
概括
较小的5毫米光区直径在orthokeratology镜头显著减少轴长延长与6毫米直径相比. 较小的治疗区域大小是轴长度延长的最佳预测指标.
科学领域:
- 眼科医生 眼科 眼科
- 眼镜测量是指眼睛的测量.
- 角质折射疗法角质折射疗法
背景情况:
- 角膜折射疗法 (CRT) 的目的是控制轴长度延伸.
- 调查不同的后光区直径 (BOZD) 对于优化CRT至关重要.
- 了解对更高阶异常 (HOA) 和处理区 (TZ) 大小的影响至关重要.
研究的目的:
- 为了评估CRT与不同BOZD在轴长度 (AL) 延伸上的有效性.
- 为了比较不同BOZD之间的HOA,TZ大小和Zernike失焦系数.
- 为了确定预测AL延长的最佳参数.
主要方法:
- 涉及7至14岁儿童的前性队列研究,使用5毫米或6毫米BOZD正体K镜头.
- 在基线和随访期间测量了轴长,角膜地形,HOA和Zernike失焦系数.
- 使用多变量回归和ROC曲线分析来评估关联和预测值.
主要成果:
- 在12个月后,5毫米BOZD组的AL变化显著小 (0.13毫米),而不是6毫米组 (0.27毫米).
- 5毫米组具有较小的TZ尺寸和更高的泽尼克失焦系数和HOA.
- 较小的TZ尺寸和较大的年龄被确定为防止AL延长的保护因素.
结论:
- 5毫米的BOZD显示出对AL延长的优越控制,与6毫米的BOZD相比,它减少了51.8%.
- 5毫米的BOZD导致了更小的TZ,更高的Zernike失焦,以及更高的HOAs.
- TZ大小是AL延长的最有效预测因素,直径<3.82毫米可能每年将延长限制在<0.2毫米.
相关概念视频
01:16Focusing of Light in the Eye
2.9K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.9K
01:27Open Angle Glaucoma: Treatment
458
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
458